Dec 19, 2017 11:00 am UTC| Business
Las Vegas, NV, Dec. 19, 2017 -- mCig, Inc. (OTCMKTS:MCIG), a diversified company servicing the legal cannabis, hemp, and CBD markets, is pleased to announce that it has expanded its cryptocurrency portfolio, creating...
Lubn Inc. Showcases IoT-Based Property Management Platform at CES Eureka Park
Dec 19, 2017 11:00 am UTC| Business
BELLEVUE, Wash., Dec. 19, 2017 -- Lubn Inc., the creator of the world's most flexible and innovative property access and management platform, today announced their IoT hardware and software solution will be showcased at...
Amphastar Announces Approval for Sodium Nitroprusside Injection, USP
Dec 19, 2017 11:00 am UTC| Business
RANCHO CUCAMONGA, Calif., Dec. 19, 2017 -- Amphastar Pharmaceuticals, Inc., (NASDAQ: AMPH) announced that today the U.S. Food and Drug Administration (“FDA”) granted approval of its abbreviated new drug application...
Awingu and Barracuda Networks to Deliver a Unified Workspace for the Hybrid Cloud
Dec 19, 2017 11:00 am UTC| Business
NEW YORK, Dec. 19, 2017 -- Awingu (www.awingu.com), the unified, browser-based workspace, today announced a technology relationship with Barracuda Networks, Inc. (www.barracuda.com) (NYSE:CUDA), a leading provider of...
Dec 19, 2017 11:00 am UTC| Business
BEDMINSTER, N.J., and DUBLIN, Ireland, Dec. 19, 2017 -- Amarin Corporation plc (NASDAQ:AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular...
Chartbeat Announces the 100 Most Engaging Stories of 2017
Dec 19, 2017 11:00 am UTC| Business
NEW YORK, Dec. 19, 2017 -- Chartbeat, the leading content intelligence platform for publishers, today announces the 100 Most Engaging Stories of 2017, the articles that were read most this year based on highest Engaged...
Opthea Doses First Patient in Phase 2b Study of OPT-302 for Wet AMD
Dec 19, 2017 10:30 am UTC| Business
MELBOURNE, Australia, Dec. 19, 2017 -- Opthea Limited (ASX:OPT), a developer of novel biologic therapies for the treatment of eye diseases, announced today the dosing of the first patient in the Company’s Phase 2b trial...